$ENSC
Ensysce Biosciences, Inc. Stock $ensc

$ensc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009844 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$789.6K	$1.433M	$2.523M
YoY Change	30.93%	-12.34%	-28.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.555M	$1.192M	$6.910M
YoY Change	-31.38%	-18.01%	-63.07%
% of Gross Profit
Research & Development	$1.796M	$6.442M	$19.84M
YoY Change	-42.8%	194.44%	322.93%
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$3.351M	$7.634M	$26.75M
YoY Change	-38.01%	109.61%	14.29%
Operating Profit	-$2.561M		-$24.22M
YoY Change	-46.67%		21.9%
Interest Expense	$1.497K	-$51.86K	$109.5K
YoY Change	-109.97%	-102.61%	-117.61%
% of Operating Profit
Other Income/Expense, Net	$369.4K	$739.1K	$14.41K
YoY Change	-93.37%	-107.13%	-100.17%
Pretax Income	-$2.192M	-$5.478M	-$24.21M
YoY Change	130.49%	-45.42%	-16.94%
Income Tax
% Of Pretax Income
Net Earnings	-$2.192M	-$5.522M	-$24.21M
YoY Change	130.45%	-44.98%	-16.77%
Net Earnings / Revenue	-277.57%	-385.22%	-959.33%
Basic Earnings Per Share	-$2.08		-$11.62
Diluted Earnings Per Share	-$2.08	-$18.21	-$139.40
COMMON SHARES
Basic Shares Outstanding	15.43M shares	2.841M shares	2.159M shares
Diluted Shares Outstanding	1.054M shares		179.9K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.416M	$3.148M	$3.148M
YoY Change	-83.23%	-74.34%	-74.34%
Cash & Equivalents	$1.416M	$3.148M	$3.148M
Short-Term Investments
Other Short-Term Assets	$1.666M	$1.875M	$1.875M
YoY Change	-30.86%	-36.58%	-36.58%
Inventory
Prepaid Expenses	$1.647M	$1.847M
Receivables	$289.3K	$276.8K	$276.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.371M	$5.299M	$5.299M
YoY Change	-71.09%	-66.17%	-66.17%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$544.2K	$585.9K	$585.9K
YoY Change	-23.68%	-22.37%	-22.38%
Total Long-Term Assets	$544.2K	$585.9K	$585.9K
YoY Change	-23.68%	-22.37%	-22.38%
TOTAL ASSETS
Total Short-Term Assets	$3.371M	$5.299M	$5.299M
Total Long-Term Assets	$544.2K	$585.9K	$585.9K
Total Assets	$3.915M	$5.885M	$5.885M
YoY Change	-68.36%	-64.15%	-64.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.598M	$2.944M	$2.944M
YoY Change	66.54%	877.67%	877.68%
Accrued Expenses	$2.378M	$2.254M	$2.254M
YoY Change	34.4%	-34.34%	-34.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.267M	$4.267M
YoY Change	-100.0%	-66.53%	-66.53%
Total Short-Term Liabilities	$3.976M	$9.464M	$9.464M
YoY Change	-54.83%	-42.58%	-42.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$140.2K	$140.2K
YoY Change	-100.0%	-96.84%	-96.84%
Other Long-Term Liabilities	$91.32K	$310.3K	$310.4K
YoY Change	-89.52%	-91.5%	-91.5%
Total Long-Term Liabilities	$91.32K	$450.5K	$450.5K
YoY Change	-96.29%	-87.67%	-94.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.976M	$9.464M	$9.464M
Total Long-Term Liabilities	$91.32K	$450.5K	$450.5K
Total Liabilities	$4.067M	$9.915M	$9.600M
YoY Change	-62.96%	-59.66%	-60.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.1M	-$110.9M
YoY Change		29.19%
Common Stock	$128.00	$642.00
YoY Change		-73.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.7K	-$3.714M	-$3.714M
YoY Change
Total Liabilities & Shareholders Equity	$3.915M	$5.885M	$5.885M
YoY Change	-68.36%	-64.15%	-64.15%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.192M	-$5.522M	-$24.21M
YoY Change	130.45%	-44.98%	-16.77%
Depreciation, Depletion And Amortization		$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$3.607M	-$3.296M	-$17.89M
YoY Change	4.94%	-12.53%	117.02%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.500K
YoY Change	-100.0%
Cash From Investing Activities		$0.00	$4.500K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.875M	1.940M	$8.766M
YoY Change	-579.2%	-78.88%	-56.85%
NET CHANGE
Cash From Operating Activities	-$3.607M	-3.296M	-$17.89M
Cash From Investing Activities		0.000	$4.500K
Cash From Financing Activities	$1.875M	1.940M	$8.766M
Net Change In Cash	-$1.732M	-1.355M	-$9.117M
YoY Change	-54.71%	-125.01%	-175.53%
FREE CASH FLOW
Cash From Operating Activities	-$3.607M	-$3.296M	-$17.89M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001716947
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	ENSC	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2022	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Accretion Expense AccretionExpense		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	ENSC	Commitment Fee For Share Subscription Facility CommitmentFeeForShareSubscriptionFacility		usd
CY2022	ENSC	Warrant Modification WarrantModification		usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	ENSC	Stockbased Compensation StockbasedCompensation		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	ENSC	Non Cash Payable To Related Parties Settled In Shares NonCashPayableToRelatedPartiesSettledInShares		usd
CY2021	ENSC	Capital Contribution From Related Parties CapitalContributionFromRelatedParties		usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2022	ENSC	Share Subscription Facility Transaction Costs ShareSubscriptionFacilityTransactionCosts		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2022Q4	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees		usd
CY2022Q4	ENSC	Consultant Expenses ConsultantExpenses		usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent		usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	ENSC	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2022Q4	ENSC	Deferred Tax Liabilities Convertible Notes Embedded Derivatives DeferredTaxLiabilitiesConvertibleNotesEmbeddedDerivatives		usd
CY2021Q4	ENSC	Deferred Tax Liabilities Convertible Notes Embedded Derivatives DeferredTaxLiabilitiesConvertibleNotesEmbeddedDerivatives		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38306
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENSYSCE BIOSCIENCES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2755287
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7946 Ivanhoe Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	263-4196
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	18800000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15425584	shares
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3147702	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12264736	usd
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	276821	usd
CY2021Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	441721	usd
CY2022Q4	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	27165	usd
CY2021Q4	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	24721	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1847481	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5299169	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	15662593	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	585883	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	754756	usd
CY2022Q4	us-gaap	Assets Assets	5885052	usd
CY2021Q4	us-gaap	Assets Assets	16417349	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2943791	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	301104	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2226494	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3407533	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27315	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24874	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	4063431	usd
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	12358886	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4266610	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	12748155	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9464210	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16481666	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140148	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4440951	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	310346	usd
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	3652790	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	450494	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8093741	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9914704	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24575407	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6415062	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1233148	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6414074	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1232160	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	642	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	124	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107215977	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77967200	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110931063	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85845567	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3714444	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7878243	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-315208	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-279815	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5885052	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16417349	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2523383	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3531199	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19835875	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4690082	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6909603	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18711548	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	26745478	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	23401630	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-24222095	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19870431	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	673314	usd
CY2022	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes	-3609944	usd
CY2022	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	1137740	usd
CY2021	ENSC	Issuance Costs For Convertible Notes IssuanceCostsForConvertibleNotes	1920158	usd
CY2022	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-5756787	usd
CY2021	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	2993060	usd
CY2022	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	3737371	usd
CY2021	ENSC	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	1865403	usd
CY2022	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	6730613	usd
CY2021	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	-1438186	usd
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	3964633	usd
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	154391	usd
CY2022	us-gaap	Interest Expense InterestExpense	109525	usd
CY2021	us-gaap	Interest Expense InterestExpense	1295307	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	86223	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-282279	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14410	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9275470	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-24207685	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-29145901	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-35393	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-62190	usd
CY2022	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	913204	usd
CY2021	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	803140	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25085496	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29886851	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.62
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-29.64
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2159189	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1008227	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6658427	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262862	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	5696703	usd
CY2021	ENSC	Stock Issued During Period Value Convertible Notes StockIssuedDuringPeriodValueConvertibleNotes	2247615	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7695264	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	121764	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11565472	usd
CY2021	ENSC	Adjustments To Additional Paid In Capital Warrants Modification AdjustmentsToAdditionalPaidInCapitalWarrantsModification	56590	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-29145901	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	54250	usd
CY2022	ENSC	Stock Issued During Period Value Convertible Notes StockIssuedDuringPeriodValueConvertibleNotes	21485904	usd
CY2022	ENSC	Stock Issued During Period Value Relatede Party Payable StockIssuedDuringPeriodValueRelatedePartyPayable	191618	usd
CY2022	ENSC	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	608382	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3783240	usd
CY2022	ENSC	Transaction Costs Associated With Public Offering TransactionCostsAssociatedWithPublicOffering	-547377	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2760074	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-24207685	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-24207685	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-29145901	usd
CY2021	us-gaap	Depreciation Depreciation	151	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4500	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	60488	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	349339	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	945969	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	673314	usd
CY2022	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-5756787	usd
CY2021	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	2993060	usd
CY2022	ENSC	Loss On Issuance Of Convertible Notes LossOnIssuanceOfConvertibleNotes	-3609944	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-347566	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1071843	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	121764	usd
CY2022	ENSC	Issuance Of Liabilities Classified Warrants IssuanceOfLiabilitiesClassifiedWarrants	3737371	usd
CY2021	ENSC	Issuance Of Liabilities Classified Warrants IssuanceOfLiabilitiesClassifiedWarrants	1865403	usd
CY2022	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	6730613	usd
CY2021	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	-1438186	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11565472	usd
CY2021	ENSC	Commitment Fee For Share Subscription Facility CommitmentFeeForShareSubscriptionFacility	1124289	usd
CY2021	ENSC	Warrant Modification WarrantModification	-56590	usd
CY2022	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-3	usd
CY2021	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-1808	usd
CY2022	ENSC	Adjustments Issuance Costs For Convertible Notes AdjustmentsIssuanceCostsForConvertibleNotes	946085	usd
CY2021	ENSC	Adjustments Issuance Costs For Convertible Notes AdjustmentsIssuanceCostsForConvertibleNotes	1920158	usd
CY2022	ENSC	Debt Conversion Expens DebtConversionExpens	3964633	usd
CY2021	ENSC	Debt Conversion Expens DebtConversionExpens	154391	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	60035	usd
CY2022	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	-164900	usd
CY2021	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	441721	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1652756	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1616019	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2642686	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1423494	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1021478	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2177742	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17887439	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8242177	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4500	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4500	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	3783240	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7533915	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	14029842	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1408364	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	467774	usd
CY2022	ENSC	Transaction Costs From Public Offering TransactionCostsFromPublicOffering	547377	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262862	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6626312	usd
CY2022	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	595509	usd
CY2021	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	488543	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8765905	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20312699	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9117034	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12070522	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12264736	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194214	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3147702	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12264736	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
CY2022	ENSC	Stockbased Compensation StockbasedCompensation	1742481	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	3052	usd
CY2022	ENSC	Settlement Of Convertible Notes Into Common Stock SettlementOfConvertibleNotesIntoCommonStock	17521271	usd
CY2021	ENSC	Settlement Of Convertible Notes Into Common Stock SettlementOfConvertibleNotesIntoCommonStock	7789927	usd
CY2022	ENSC	Non Cash Payable To Related Parties Settled In Shares NonCashPayableToRelatedPartiesSettledInShares	191618	usd
CY2022	ENSC	Capital Contribution From Related Parties CapitalContributionFromRelatedParties	608382	usd
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1068950	usd
CY2022	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	399949	usd
CY2021	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	867300	usd
CY2021	ENSC	Share Subscription Facility Transaction Costs ShareSubscriptionFacilityTransactionCosts	12689764	usd
CY2022	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	913204	usd
CY2021	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	803140	usd
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_803_eus-gaap--BasisOfAccounting_zjI0LJFWVqg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_82B_zA2qDtpjPCC2">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse Stock Split</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, the Company completed a <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20221027__20221028_zcQrJEVWsIQb" title="Reverse stock split">1-for-20 reverse split</span> of its outstanding common stock. All references in these consolidated financial statements to shares and per share amounts in all periods have been retroactively restated to reflect the split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $<span id="xdx_907_eus-gaap--Cash_iI_pn5n6_c20221231_zdpkINpHEjje" title="Cash">7.8</span> million and prepaid expenses of $<span id="xdx_900_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn5n6_c20221231_zuRxcuTKNmGh" title="Prepaid expense">1.1</span> million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231_zU1KEKlj0g42" title="Debt Instrument, conversion price">0.06585</span>. The consolidated financial statements reflect the historical operations of Ensysce.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue and had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20221231_zP0MYAoiJhO" title="Accumulated deficit">110.9</span> million at December 31, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, would be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $<span id="xdx_901_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20201231_z7k2QMGFJ6ob" title="Common stock, subscriptions value">60.0</span> million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zHoGAqQrPPBe" title="Warrants issued shares">55,306</span> warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zPyc7jNx71a2" title="Warrant, exercise price">200.20</span> per share, subsequently reduced to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20221231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zht7y6GXyphk" title="Warrant, exercise price">1.40</span> at December 31, 2022 (Note 8). The Company is required to pay a commitment fee to the investor of $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zD30vp6QnJUe" title="Commitment fees">1.2</span> million with $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--FirstAnniversaryMember_zS7XgYEJstMg" title="Commitment fees">0.8</span> million due on the first anniversary of the public listing date and $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--EighteenMonthAnniversaryMember_zYHmzSO3nMw" title="Commitment fees">0.4</span> million due on the 18-month anniversary of the public listing date. The first $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JulyTwentyTwentyTwoMember_zcyiBKO1eytj" title="Commitment fees">0.8</span> million of the commitment fee was paid in July 2022 in freely tradable common stock of the Company (Note 10) and the remaining $<span id="xdx_90B_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyThreeMember_zuKg2LSWmdK3" title="Commitment fees">0.4</span> million due in January 2023 was paid in freely tradable common stock of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce Biosciences, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July and August 2022, the Company received funding under a $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_pn4n6_c20220801__20220831_zCXQWREJq8E6">8.48 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million convertible note financing agreement with the same institutional investors (the “2022 Notes”) (See Note 7 for additional information). The agreement limits the Company’s ability to execute certain debt and equity financings, including under the GEM Agreement, while the convertible notes are outstanding. Without the availability of proceeds through the GEM Agreement, existing cash resources are not sufficient to fund current planned operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20 reverse split
CY2022Q4	us-gaap	Cash Cash	7800000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1100000	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.06585
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110900000	usd
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	60000000.0	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8480000	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	20103425	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20103425	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	12217371	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-18929415	usd
CY2022	ENSC	Convertible Debt Loss On Issuance Of Fair Value Disclosures ConvertibleDebtLossOnIssuanceOfFairValueDisclosures	3609944	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-12487400	usd
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	4203579	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	310346	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	4513925	usd
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	16799837	usd
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	3303588	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_z8bSxKnqPbng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z8iQ4LPLOfY6">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zVJHafIFGt7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zde8vV8o4wOc">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce Biosciences, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Consolidated Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Depreciation Depreciation	151	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15900000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	8500000	usd
CY2021Q4	ENSC	Consultant Expenses ConsultantExpenses	1342479	usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	610000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4513925	usd
CY2018Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5100000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	10700000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2523383	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3531199	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2523383	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3531199	usd
CY2022Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	214308	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25085496	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29886851	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2159189	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1008227	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.62
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-29.64
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2902646	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	769006	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2902646	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	769006	shares
CY2022Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	1300473	usd
CY2021Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2124008	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	445583	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	733234	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	101425	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	74173	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1847481	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	1332713	usd
CY2021Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	388997	usd
CY2022Q4	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	400000	usd
CY2021Q4	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	800000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	421530	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	138086	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	72251	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	67939	usd
CY2021Q4	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees	60032	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2226494	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3407533	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	310346	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3652790	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	310346	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3652790	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	21600000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	27316	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	31756	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	41418	usd
CY2022Q4	ENSC	Annual Bonues Target Percentage AnnualBonuesTargetPercentage	75	pure
CY2022	ENSC	Annual Bonus Amount AnnualBonusAmount	400000	usd
CY2021Q4	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses	1342479	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4100537	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	18450	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	287771	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	4406758	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	14032528	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	163517	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2993061	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	17189106	usd
CY2022	ENSC	Stated Interest Accrual StatedInterestAccrual	9909	usd
CY2021	ENSC	Stated Interest Accrual StatedInterestAccrual	251857	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	945969	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	9909	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	1197826	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08	pure
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	200000	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08	pure
CY2022	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	399949	usd
CY2022	ENSC	Financed Insurance Premiums Remains Outstanding FinancedInsurancePremiumsRemainsOutstanding	203179	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	310963	shares
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	67899	shares
CY2021Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5800000	usd
CY2021Q1	ENSC	Termination Of Common Stock Issued TerminationOfCommonStockIssued	25000	shares
CY2021Q2	ENSC	Deferred Underwriting Common Stock Issued DeferredUnderwritingCommonStockIssued	6250	shares
CY2022Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	300000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6600000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.40
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q4	ENSC	Transaction Costs TransactionCosts	500000	usd
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	945063	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	93400	shares
CY2021Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-06-30
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	55306	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.40
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	18058	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36116	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	152.60
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	152.60
CY2021Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-09-23
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	233394	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.17
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-06-29
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-08-08
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222191	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10207306	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	114550	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	77.30
CY2022	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Grants SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGrants	P8Y4M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	20493	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	43.31
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	316248	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.96
CY2022	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y6M10D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	279306	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	61.57
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	316248	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	58.96
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y6M10D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7661	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9587	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0152	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0314	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.24
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	361863	usd
CY2022	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Period Expected To Be Recognized SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized	P1Y7M9D
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10357559	shares
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1600	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5083614	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6120640	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-175164	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-131962	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	-234214	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	1620341	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	480248	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	303499	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-278940	usd
CY2022	ENSC	Income Tax Reconciliation Share Subscription Facility Transaction Costs IncomeTaxReconciliationShareSubscriptionFacilityTransactionCosts	20335	usd
CY2021	ENSC	Income Tax Reconciliation Share Subscription Facility Transaction Costs IncomeTaxReconciliationShareSubscriptionFacilityTransactionCosts	2664850	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1028988	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	501451	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	54263	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	371784	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-78227	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-139213	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6222110	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2034983	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26726066	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25068127	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4164187	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3164799	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3729483	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1173158	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	915675	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	265677	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	687422	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36058571	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29836023	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36052644	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29830534	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5927	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5489	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5927	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5489	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5927	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5489	usd
CY2022	us-gaap	Tax Credit Carryforward Description TaxCreditCarryforwardDescription	carryforward indefinitely and be available to offset up to 80% of future taxable income each year.
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1135179	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	968445	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	341108	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	171977	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	48026	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5243	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1428261	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1135179	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1400000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1100000	usd
CY2022	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
CY2021	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	46062	shares
CY2022Q4	us-gaap	Share Price SharePrice	1.40
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6.6	shares

Files In Submission

Name	View Source	Status
ensc-20221231_cal.xml	Edgar Link	unprocessable
ensc-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-009844-index-headers.html	Edgar Link	pending
0001493152-23-009844-index.html	Edgar Link	pending
0001493152-23-009844.txt	Edgar Link	pending
0001493152-23-009844-xbrl.zip	Edgar Link	pending
ensc-20221231.xsd	Edgar Link	pending
ex14.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
ensc-20221231_pre.xml	Edgar Link	unprocessable
ensc-20221231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENSC
Ensysce Biosciences, Inc. Stock $ensc

2023 Q1 Form 10-K Financial Statement

#000149315223009844 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC Ensysce Biosciences, Inc. Stock $ensc

2023 Q1 Form 10-K Financial Statement

#000149315223009844 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC
Ensysce Biosciences, Inc. Stock $ensc